Test Price
2,800 AED✅ Home Collection Available
RAD51D Gene (Breast-Ovarian Cancer Susceptibility, Type 4) Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- ✔99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited molecular diagnostics at DNA Labs UAE.
- 📦VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- 📞Post-Test Clinical Guidance – Telephonic result interpretation by a DHA-licensed Consultant Medical Geneticist.
- 💳Direct Insurance Billing – WhatsApp verification at +971 54 548 8731.
The RAD51D genetic test employs Next-Generation Sequencing (NGS) to detect germline mutations in the RAD51D gene, which are associated with a significantly elevated risk of hereditary breast and ovarian cancer (HBOC) type 4. This analysis delivers a clinically actionable risk profile for high-risk families in the UAE, enabling tailored surveillance and preventive strategies under DHA regulatory oversight.
Test Overview & Methodology
The RAD51D gene (located on chromosome 17q12) encodes a key protein involved in homologous recombination repair of DNA double-strand breaks. Pathogenic variants in RAD51D confer a lifetime breast cancer risk of approximately 20–40% and an ovarian cancer risk of 10–20%, making this test essential for families with a strong history of these malignancies. DNA Labs UAE utilises Next-Generation Sequencing (NGS) with full gene coverage including all coding exons and flanking intronic regions, ensuring detection of single nucleotide variants, small insertions/deletions, and copy number variations.
| Feature | DNA Labs UAE RAD51D NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity and specificity | ~95% – limited to targeted exons |
| Methodology | NGS (Next-Generation Sequencing) with full gene coverage | Capillary Sanger sequencing |
| Turnaround Time | 3–4 weeks (fast-track available upon request) | 6–8 weeks |
| Sample Type | Peripheral whole blood or saliva (Oragene OG-500 kit) | Blood only |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I recognise that genetic testing for hereditary cancer susceptibility carries profound implications for patients and their families. The RAD51D analysis provides a personalised risk map that must be contextualised within the full pedigree and clinical presentation. I strongly recommend post-test genetic counselling to ensure informed medical decision-making and appropriate risk management strategies."
Advisory Guidelines for Patients
- This test is designed for individuals aged 18 years and above who have a personal or family history suggestive of hereditary breast and ovarian cancer syndrome.
- Informed consent must be obtained prior to sample collection, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Results should be reviewed with a qualified healthcare professional; genetic counselling is included in the service package.
- A negative result does not eliminate the possibility of a hereditary cancer syndrome caused by other genes.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals under 18 years without court-approved guardian consent as per UAE federal regulations.
- Exclusion: Patients unable to provide informed consent or with acute psychiatric instability requiring immediate medical attention.
- Exclusion: Active haematological conditions that contraindicate blood draw safety (assessed by the mobile phlebotomy team prior to collection).
- Red Flag: This test is NOT intended for emergency cancer diagnosis. If you experience a new breast lump, pelvic mass, or sudden severe pain, visit the nearest emergency department immediately.
- Red Flag: Positive results may cause psychological distress; 24/7 psychological support is available upon request through DNA Labs UAE.
- Medication Caution: Do not discontinue or alter any prescribed medication without consulting your treating physician.
Patient FAQ & Clinical Guidance
1. What does the RAD51D test reveal and how does it help me?
This genetic analysis identifies pathogenic variants in the RAD51D gene that substantially elevate breast and ovarian cancer susceptibility. The results enable personalised surveillance strategies (e.g., breast MRI, transvaginal ultrasound) and risk-reducing options, including prophylactic surgery for high-risk carriers. A negative result provides reassurance when family history is strong but does not eliminate baseline population risk.
2. Is this test covered by UAE health insurance?
Direct billing verification is handled via WhatsApp at +971 54 548 8731. Most major UAE insurers cover hereditary cancer panels when ordered by an oncologist or genetic counsellor. DNA Labs UAE provides real-time policy checking and issues a pre-authorisation letter before sample collection to prevent unexpected out-of-pocket costs.
3. How is the sample collected and is it painful?
A DHA-certified mobile phlebotomist collects a peripheral whole blood sample via gentle venipuncture during a home visit. The procedure takes less than five minutes and most patients describe only a brief pinch. Alternatively, a saliva sample using the Oragene OG-500 kit can be arranged. All samples are transported under temperature-controlled cold chain to our Dubai Healthcare City laboratory.
4. How long does it take to get results?
The standard turnaround time is 3–4 weeks from sample receipt at the laboratory. A fast-track option is available upon request for an additional fee. Results are delivered electronically via a secure patient portal and are discussed in a telephonic consultation with a genetic counsellor.
5. What happens if my test result is positive?
A positive result indicates the presence of a pathogenic RAD51D variant. The genetic counsellor will explain the implications, provide lifetime risk estimates, and guide you through available management options including enhanced screening, chemoprevention, and prophylactic surgery. Family member testing and reproductive counselling options are also discussed.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the UAE's legal framework for healthcare and data protection. All genetic testing services adhere to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of personal genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating electronic health records and telemedicine practices.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring informed consent, patient safety, and clinical accountability.
- Dubai Health Authority (DHA) Standards – facility licensed under number 1143, ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Patient genetic information is encrypted, access-controlled, and never shared with third parties without explicit written consent. You have the right to request deletion of your data at any time, subject to applicable legal retention periods.
Clinical & Logistical Metadata
| Test Name | RAD51D Gene (Breast-Ovarian Cancer Susceptibility, Type 4) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (fast-track available) |
| Sample Type / Matrix | Peripheral Whole Blood or Saliva (Oragene OG-500 Kit) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | Z15.01, Z15.02 |
| LOINC Code | 94468-9 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians